Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

BICO moves to Nasdaq Stockholm’s Large Cap Segment

Today BICO, the leading bio convergence company, announced it will, based on Nasdaq’s annual review of the market capitalization segments, be moved from the Mid Cap to the Large Cap segment on January 3, 2022. “This move to Nasdaq Stockholm’s large cap segment is a testament BICO’s strong growth and momentum in the last year,” says Erik Gatenholm, CEO and co-founder of BICO. “We are continuing to develop our bio convergence offering enabling our customers to achieve Health 4.0. and create the future of health.” The move comes just five years after the company was first listed on the

K-Fastigheter moves to Nasdaq Stockholm Large Cap segment

As of 3 January 2022, shares in K-Fast Holding AB (“K-Fastigheter”) will be trading on Nasdaq Stockholm Large Cap segment after Nasdaq has completed its annual review of the market capitalization of listed companies. The companies on this list have a market capitalisation of at least EUR 1 billion.“In December 2010, we started K-Fastigheter with eight apartments on the books, to step from two almost empty pockets into the top segment of the stock market in just eleven years feels fantastic. A feat for which I have fantastic employees and partners to thank. A big step only two years after

Advania strengthening the security offering with the acquisition of Painkiller

Advania AB (“Advania”) will further grow products and services to help customers on their digital journey by joining forces with the highly skilled, Norwegian based security specialist Painkiller AS (“Painkiller”). Key transaction highlights · Advania has reached a definitive agreement to acquire 100% of Painkiller AS, from the employees and other shareholders. · Advania, with a heritage dating back to its inception in Iceland in 1939, is a leading IT service provider in the Northern Europe with operations in Sweden, Iceland, Norway, UK, Denmark and Finland. ·

NIB finances construction of Ylva’s green building complex Lyyra in Helsinki

The Nordic Investment Bank (NIB) has signed a 7-year loan agreement to finance the construction of the Lyyra building complex in Hakaniemi, Helsinki, which aims to achieve LEED Platinum certification upon completion of currently ongoing construction work by 2023.The loan NIB has signed with Helsingin Lyyra KY will finance facilities for office, hotel, retail, housing, and parking services. NIB’s share of the EUR 65 million co-financing with Nordea is EUR 40 million. The Lyyra complex is situated at Toinen linja 7 and Siltasaarenkatu 13 in the eastern downtown area Hakaniemi in Helsinki, and

Ovzon receives renewed order from Airbus for the UK MoD

Ovzon has secured the contract renewal from Airbus for the UK Ministry of Defence (UK MoD). The renewal is for the use of Ovzon’s SATCOM-as-a-Service which includes satellite capacity and Ovzon’s industry-leading mobile satellite terminals.The order is a 6-month extension of an initial order received earlier in 2021. The order value is 500,000 USD with contract starting in February 2022. UK MoD have already used Ovzon services successfully in different scenarios and needs. Among other things, Ovzon’s ultra-small mobile satellite terminals have been used to build a temporary network over a

Bioretec’s financial information and Annual General Meeting in 2022

Bioretec Ltd                       Company announcement       20 December 2021 at 10:00 a.m. EETBioretec will publish the following financial information in 2022: · Financial Statements Bulletin January-December 2021 on Thursday, 17 February 2022 · Half-year Report January-June 2022 on Friday, 12 August 2022 The Annual Report for the year 2021 will be published during the week 10/2022, at the latest. Bioretec adheres to a 30-day silent period in its communication with investors and the media preceding the publication of Financial Statements Bulletin and Half-year Report.

European consumers expect to take on additional debt over Christmas period

“Bringing family together and meeting expectations”. These are the reasons why one in five Europeans take on additional debt at Christmas, according to Intrum’s annual consumer report conducted in 24 European countries. Although households with families are more likely to take on debt to pay for food and presents than the average consumer, the age group being most likely to do so is Generation Z (age 18-21).“While one in three consumers feel that their financial wellbeing has deteriorated post-Covid, many also feel the urge to take on substantial levels of debt to celebrate the upcoming

Successful first subscale test flight for Heart ES-19 electric aircraft

December 17th marked another milestone in the development of pioneer electric aircraft Heart ES-19. For the first time, a scale model of the plane took flight at the Heart Aerospace HQ’s at Säve Airport in Gothenburg, Sweden.”The most dramatic thing about the test flight was how undramatic it was. The plane performed exactly as we predicted - soaring effortlessly through the air, with a precision take-off and landing. This test flight validated what we already knew - that the ES-19 aerodynamic design is inherently stable and safe”, says Anders Forslund, founder and CEO of Heart Aerospace.

BioStock: Cyxone CRO agreement signals Phase IIb RA trial moving forward as planned

In the preparation for the coming phase IIb trial with Rabeximod in rheumatoid arthritis, biotech company Cyxone has entered an Early Operations Agreement with an internationally renowned clinical contract research organisation. BioStock contacted CEO Tara Heitner to learn more.Read the interview with Cyxone's CEO Tara Heitner at biostock.se: https://www.biostock.se/en/2021/12/cyxones-cro-agreement-signal-phase-iib-ra-trial-is-moving-forward-as-planned/ This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/

Positive study results confirm the unique capability of using PreciseInhale in a clinical setting

(Stockholm, 20 December, 2021) Results from a recently completed clinical study demonstrate that PreciseInhale® has reached its clinical objectives. CEO Manoush Masarrat: “This is one of the most important milestones to date in our company’s history. It unlocks new markets with an estimated market potential of minimum 5 billion SEK, plus it gives the entire inhalation research sector new capabilities including a new benchmark for aerosol precision and dosing.”Topline data confirm that ISAB’s flagship aerosol generating system PreciseInhale has reached its clinical objectives, with no

Notice to the Extraordinary General Meeting of Enersense International Plc

Enersense International Plc Stock Exchange Release, 20 December at 9:45 a.m.Notice is given to the shareholders of Enersense International Plc (the “Company”) to the Extraordinary General Meeting (the “General Meeting”) to be held on Tuesday 11 January 2022 at 10:00 a.m. (EET) at the office of Hannes Snellman Attorneys Ltd at Eteläesplanadi 20, 00130 Helsinki, Finland. The Company’s shareholders and their proxy representatives may participate in the General Meeting and exercise shareholder rights only by voting in advance and by making counterproposals and submitting questions in advance

SBB and OBOS begin strategic collaboration - SBB sells its shares in Solon Eiendom ASA to a company jointly owned by SBB and OBOS, Solon Eiendom Holding AS

Samhällsbyggnadsbolaget I Norden AB (“SBB”) and OBOS have initiated a strategic collaboration with a focus on social sustainability. The collaboration includes the development of more attractive housing opportunities for OBOS members in Norway and Sweden and aims to support SBB’s ambition to contribute to the construction of important social infrastructure in the Nordic region. As a first step in the collaboration, SBB has sold its shares in Solon Eiendom ASA (“Solon”) to a company jointly owned by SBB and OBOS, Solon Eiendom Holding AS (“Solon Holding”). The share price in the transaction

Control your Eberspächer heater with Modul-Connect

Modul-System’s Modul-Connect app now supports the control of Eberspächer heaters. This project is a collaboration where Modul-System’s innovative and robust platform and Eberspächer’s world-leading technology have been combined and made it easier than ever for you to control your heater.Modul-System is one of the world’s leading manufacturers of van racking systems and vehicle equipment for the LCV market and have over the years developed Modul-Connect, a system for monitoring and controlling various functions in your vehicle through an app and also by remote switch panels. Now Modul-

DUG launches on world’s largest dedicated online supermarket, Ocado

Veg of Lund has signed an agreement with Ocado Retail to stock and sell its plant-based drink DUG from January 2022. Ocado Retail, a joint venture between Ocado Group and Marks & Spencer, is the UK’s fastest growing supermarket and delivers to around three quarters of British households.With an extensive range of almost 50,000 products, Ocado has spent the last twenty years delivering a market-leading online grocery service. As a sustainable retailer with the lowest food waste of any British grocer, Ocado has a dedicated eco shop, helping conscious consumers find greener options when

Skanska builds data center in London, UK, for GBP 53M, about SEK 620M

Skanska has signed a contract with VIRTUS to build a new data center in London’s metro, UK. The contract is worth GBP 53M, about SEK 620M, which will be included in the order bookings for Europe for the fourth quarter of 2021.The contract is for the design and build of the LONDON11 data centre. This includes the build and fit out of six new data halls, construction of external steelwork plant gantries, plant rooms for mechanical and electrical and public health services (MEPH), all MEPH infrastructure across the site and office fit out. Construction work will begin in December 2021 and

Early redemption of subordinated Tier 2 notes issued by Resurs Bank AB (publ)

On 17 January 2022 Resurs Bank AB (publ) will redeem all of its outstanding subordinated callable Tier 2 notes with ISIN SE0009522212, SEK 300 000 000 issued on 17 January 2017.Resurs Bank, a wholly owned subsidiary of Resurs Holding AB (Nasdaq Stockholm: RESURS), will use its right to redeem the notes early according to the terms and conditions. All outstanding notes will be redeemed in full at their nominal amount, together with accrued but unpaid interest. The redemption date is 17 January 2022. The redemption price will be paid to each person who is registered as a holder in the debt

Early redemption of subordinated Tier 2 notes issued by Resurs Bank AB (publ)

On 17 January 2022 Resurs Bank AB (publ) will redeem all of its outstanding subordinated callable Tier 2 notes with ISIN SE0009522212, SEK 300 000 000 issued on 17 January 2017.Resurs Bank will use its right to redeem the notes early according to the terms and conditions. All outstanding notes will be redeemed in full at their nominal amount, together with accrued but unpaid interest. The redemption date is 17 January 2022. The redemption price will be paid to each person who is registered as a holder in the debt register kept by Euroclear Sweden on 10 January 2022. The redemption has been

Nordisk Bergteknik acquires Bröderna Anderssons Grus based in Västerbotten

Nordisk Bergteknik has entered into an agreement regarding the acquisition of all shares in Bröderna Anderssons Grus, a contractor within crushed rock and material delivery based in Burträsk, in the region of Västerbotten. Through the acquisition Nordisk Bergteknik broadens the extent of its offering and continues to strengthen its position and presence in upper Norrland.Bröderna Anderssons Grus AB was founded in 1976 and today has a turnover of approximately SEK 90 million on annual basis with an EBIT margin on par with Nordisk Bergteknik’s long-term financial targets. The company employs

Neste donates EUR 1 million to universities in Finland

Neste Corporation, Press Release, 20 December 2021 at 9.30 a.m. (EET)Neste will donate a total of EUR 1 million to universities in Finland to support the research and education in the chemical industry and to further strengthen the collaboration between the industry and the scientific community. The donation will be targeted to Aalto University and Åbo Akademi University, with whom Neste has established long-term strategic cooperation . In

Mandatory notification of trade

Anooj Unarket, Board member of Otello Corporation ASA, has on behalf of certain related parties, as of 17th December 2021, acquired interests in shares of Otello Corporation ASA. The balance of Anooj Unarket and related parties’ holdings after the transaction totals 26,654,720 shares. Please refer to the attached notification of trading for further details. This information is subject to disclosure requirements in regulation EU 596/2014 article 19 number 3 and the Norwegian Securities Trading Act section 5-12.

BioStock: Cereno Scientific expands patent rights for CS1

With Cereno Scientific’s lead programme CS1 currently in phase II, the company is working towards future-proofing its commercial positioning. Throughout 2021, the biotech company has seen its patent portfolio for CS1 grow to cover most major global markets with the first two patent families. Last week, Cereno announced receiving its first patent in the third patent family for CS1.Read the article at biostock.se: https://www.biostock.se/en/2021/12/cereno-scientific-expands-patent-rights-for-cs1/ This is a press release from BioStock - Connecting Innovation & Capital. https://www.

XNK Therapeutics strengthens its scientific network with two more advisors

December 20[th], 2021 XNK Therapeutics AB (“XNK”) today announced the appointment of Dr. Gunilla Enblad, Professor of oncology at Uppsala University, and Dr. Rizwan Romee, Associate Professor of Medicine at Harvard Medical School, as scientific advisors. Together with the other advisors, they will play a key role in the future development of XNK’s proprietary technology platform of natural killer (NK) cell therapies within plasma cell disorders and hematological malignancies.Dr. Rizwan Romee is an Associate Professor of Medicine at Harvard Medical School and director of the

Tezspire approved in the US for severe asthma

20 December 2021 07:05 GMT Tezspire (tezepelumab) approved in the US for severe asthma First and only biologic to consistently and significantly reduce exacerbations in a broad population of severe asthma patients Only biologic for severe asthma approved with no phenotype or biomarker limitations AstraZeneca and Amgen's Tezspire (tezepelumab-ekko) has been approved in the US for the add-on maintenance treatment of adult and paediatric patients aged 12 years and older with severe asthma.[1] Tezspire was approved following a Priority Review 

There are no items matching the current filter
There are no more items matching the current filter
Back to top